All News

According to the CDC, major interventions are in need among at-risk populations in order to reach a goal of 90% decrease of HIV infections in 10 years.

The CDC has declared immunizations one of the greatest health achievements of the 20th century, but vaccination rates among adults remain suboptimal.

Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer.

Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) is indicated for subcutaneous administration in certain patients with HER2-positive early and metastatic breast cancer.

IBSA Pharma’s levothyroxine sodium (Tirosint-SOL) oral solution is now available in the United States market for the treatment of hypothyroidism and pituitary thyrotropin suppression.

Approved by the FDA in July 2018, Perseris is the first once-monthly, subcutaneous risperidone-containing, long-acting injectable available in the United States.

Top news of the day from across the health care landscape.

The new class of smart drugs has the ability to bring the toxic payload directly to the cancer cells.

Continued consumption of peanuts was associated with positive quality of life and perceptions of safety following immunotherapy treatment for peanut allergy.

For this edition of Throwback Thursday, we look back in time at Jonas Salk and his research.

Amazon announced their acquisition of the online pharmacy PillPack, which prides itself on customer service by offering presorted medication, and home delivery, in a press release in June of 2018.

The controlled injection offers patients with plaque psoriasis the ease of self-injection.

The controlled injection offers patients with plaque psoriasis the ease of self-injection.

The findings reinforce the effectiveness of the HPV vaccine in preventing cervical cancer.

Not according to Richard Koch in his book The 80/20 Principle: The Secret to Success by Achieving More with Less.

Top news of the day from across the health care landscape.

In a real-world setting, long-term outcomes were more favorable following early intensive therapy when compared with first-line moderate-efficacy diseased modifying therapy.

A 10 mg twice daily dose of tofacitinib (Xeljanz, Xeljanz XR, Pfizer) used in patients with rheumatoid arthritis increased the risk of blood clots in the lungs and death in a safety clinical trial.

In order for a substantial decrease of HIV infections in the United States, there needs to be a rapid expansion of prevention and treatment for individuals at risk.

Methylprednisolone Tablets had annual sales of approximately $114.3 million in the United States.

Top news of the day from across the health care landscape.

The trial aimed to evaluate the survival rate of patients with metastatic hormone-sensitive prostate cancer who were treated with the combination of enzalutamide and androgen deprivation therapy.

The higher dose is only approved for patients with ulcerative colitis, and not for RA.